Treatment options for hepatocellular carcinoma (HCC) patients presenting with portal vein tumor thrombus (PVTT) are limited, but recent clinical studies have shown promising results using combination therapies, including the anti-PD-1 immunotherapeutic camrelizumab and the VEGFR2 inhibitor apatinib. Additionally, advances in stereotactic body radiotherapy (SBRT) facilitate targeting high doses of radiation to tumors while reducing damage to neighboring healthy tissue. In a prospective study, Hu and colleagues assess the safety and efficacy of camrelizumab plus apatinib treatment with or without SBRT as first-line therapy for HCC patients with PVTT. The authors found that safety profiles were similar among patients who received SBRT and those who did not, with 21.7% of patients reporting grade ≥3 treatment-related adverse events. The SBRT-treated cohort had a median overall survival (OS) of 12.7 months and a median progression-free survival (PFS) of 4.6 months compared with the non-SBRT-treated cohort (median OS 8.6 months; median PFS 2.5 months)....

You do not currently have access to this content.